Design and rationale of a prospective, randomized, non-inferiority trial to determine the safety and efficacy of the Biolimus A9™ drug coated balloon for the treatment of in-stent restenosis: First-in-man trial (REFORM)
Robert A. Byrne(Mater Private Hospital), Fernándo Alfonso(Hospital Universitario de La Princesa), Samuel Copt, Jochen Wöhrle, Himanshu Rai(Deutsches Herzzentrum München), Seán Fitzgerald(Discovery Laboratories (United States)), Keith G. Oldroyd(Biosensores (Spain)), Peter O’Kane(Royal Bournemouth Hospital), Darren Mylotte(University Hospital Galway), Joo‐Yong Hahn(Samsung Medical Center), Marie‐Claude Morice(Institut Cardiovasculaire Paris Sud), Bernardo Cortese, Diane Schuette(Biosensors International Group (Singapore)), Jasper Trevelyan(Worcestershire Royal Hospital), Manel Sabaté(Hospital Clínico San Carlos), Ralph Tölg(Segeberger Kliniken)
Cited by 17
Related Papers
A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization
|New England Journal of Medicine|2002|4k
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
|The Lancet|2007|1.4k
Randomized Trial of Preventive Angioplasty in Myocardial Infarction
|New England Journal of Medicine|2013|1k
Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina
|Journal of the American College of Cardiology|2018|772
Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction
|New England Journal of Medicine|2022|566